N^α-Ethylhistamine | 91775-07-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N^α-Ethylhistamine
• 英文别名: ethyl-[2-(1(3)H-imidazol-4-yl)-ethyl]-amine；Aethyl-[2-(1(3)H-imidazol-4-yl)-aethyl]-amin；4-Ethylaminoethyl-imidazol；4-(2-(Ethylamino)ethyl)imidazole；N-ethyl-2-(1H-imidazol-5-yl)ethanamine
• CAS: 91775-07-4
• 化学式: C₇H₁₃N₃
• 分子量: 139.2
• InChiKey: OJGUJIJTRGMFGI-UHFFFAOYSA-N

物化性质

• 沸点：
  317.3±17.0 °C(Predicted)
• 密度：
  1.026±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-Ethyl-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidin-5-on Hydrochlorid 在 氢氧化钾 作用下， 反应 12.0h， 以70%的产率得到N^α-Ethylhistamine
  参考文献：
  名称：

  组胺类似物的构效关系，第 21 版。Nα-取代组胺的合成和作用

  摘要：

  介绍了 Nα 取代的组胺并检查了它们对组胺 H1 和 H2 受体的激动作用。

  DOI：

  10.1002/ardp.19803130905

文献信息

• Benzothiophene derivatives
  申请人：Hubbs Jed Lee

  公开号：US20090082308A1

  公开（公告）日：2009-03-26

  The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一类新型的苯并噻吩酰胺衍生物。这些羟肟酸化合物可用于治疗癌症。苯并噻吩酰胺化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导终末分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。该发明的化合物也可用于预防和治疗TRX介导的疾病，如自身免疫性、过敏性和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供了包含羟肟酸衍生物的药物组合物和这些药物组合物的安全剂量方案，易于遵循，并在体内产生治疗有效量的羟肟酸衍生物。
• METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS
  申请人：Landry Donald W.

  公开号：US20090292119A1

  公开（公告）日：2009-11-26

  The present invention provides improved methods for synthesizing novel benzothiazepine compounds. In particular, the invention relates to a new method that generally is used to make the substituted 2,3,4,5-tetrahydro-1,4-benzothiazepine compounds of a general formula which then may be used to make many other benzothiazepine compounds.

  本发明提供了改进的合成新型苯并噻吩化合物的方法。具体来说，本发明涉及一种新方法，通常用于制备一般式的取代2,3,4,5-四氢-1,4-苯并噻吩化合物，然后可以用于制备许多其他苯并噻吩化合物。
• HISTAMINE H3 AGONIST FOR USE AS THERAPEUTIC AGENT FOR LIPID/GLUCOSE METABOLIC DISORDER
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1938838A1

  公开（公告）日：2008-07-02

  The present invention provides a histamine receptor H3 protein agonist (e.g. Imetit) used for anti-obesity or suppression of food intake. In addition, the present invention also provides a method for assaying a compound having a histamine receptor H3 protein as a target of drug discovery, and a compound obtained by the aforementioned assay method. According to the present invention, it becomes possible to provide a novel intended use of a histamine receptor H3 protein agonist for anti-obesity or suppression of food intake. Moreover, it also becomes possible to provide a method for assaying a compound having the aforementioned protein as a target of drug discovery, and a compound obtained by the aforementioned assay method.

  本发明提供了一种组胺受体H3蛋白激动剂（如伊美替特），用于抗肥胖或抑制食物摄入。此外，本发明还提供了一种以组胺受体 H3 蛋白为药物发现靶点的化合物的检测方法，以及通过上述检测方法获得的化合物。根据本发明，有可能提供组胺受体 H3 蛋白激动剂在抗肥胖或抑制食物摄入方面的新型预期用途。此外，本发明还提供了一种以上述蛋白为药物发现靶点的化合物的检测方法，以及通过上述检测方法获得的化合物。
• 108. 4(5)-β-Alkylaminoethylglyoxalines
  作者：B. Garforth、F. L. Pyman

  DOI：10.1039/jr9350000489

  日期：——
• Studies of Imidazole Compounds. IV. Derivatives of 4-Ethylimidazole
  作者：Charles F. Huebner、Robert A. Turner、Caesar R. Scholz

  DOI：10.1021/ja01180a017

  日期：1949.12